News for Oramed Pharmaceuticals Stock (ORMP)

Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

PRNewsWire • 03/16/21

Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021

PRNewsWire • 03/04/21

Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

PRNewsWire • 01/21/21

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

PRNewsWire • 01/07/21

Oramed Reports Positive First in Human Data from Oral Leptin Study

PRNewsWire • 12/23/20

Oramed Initiates Phase 2 NASH Trial of Oral Insulin

PRNewsWire • 12/02/20

Oramed Initiates Phase 3 Trial of Oral Insulin

PRNewsWire • 11/24/20

Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020

PRNewsWire • 11/12/20

Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference

PRNewsWire • 10/28/20

Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA

PRNewsWire • 10/16/20

Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting

PRNewsWire • 09/21/20

Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

PRNewsWire • 09/15/20

Insulin in Pill Form Would Be a Bonanza for Oramed

GuruFocus • 07/08/20

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

PRNewsWire • 06/15/20